Aravive Competitors

Aravive (NASDAQ:ARAV) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Aravive and Evolus, as provided by MarketBeat.

Aravive presently has a consensus target price of $25.20, suggesting a potential upside of 420.66%. Evolus has a consensus target price of $15.00, suggesting a potential upside of 73.01%. Given Aravive's stronger consensus rating and higher possible upside, equities analysts plainly believe Aravive is more favorable than Evolus.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 21.7% of Evolus shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Comparatively, 10.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Aravive and Evolus' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Aravive and Evolus' revenue, earnings per share (EPS) and valuation.

Aravive has higher earnings, but lower revenue than Evolus. Aravive is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aravive has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500. Comparatively, Evolus has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

Summary

Aravive beats Evolus on 11 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Aravive and UroGen Pharma's revenue, earnings per share (EPS) and valuation.

Aravive has higher revenue and earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and UroGen Pharma's net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 71.6% of UroGen Pharma shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Comparatively, 12.0% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Aravive has a beta of 3.2, suggesting that its share price is 220% more volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Aravive and UroGen Pharma, as provided by MarketBeat.

Aravive presently has a consensus target price of $25.20, suggesting a potential upside of 420.66%. UroGen Pharma has a consensus target price of $40.50, suggesting a potential upside of 124.50%. Given Aravive's higher possible upside, equities analysts plainly believe Aravive is more favorable than UroGen Pharma.

Summary

Aravive beats UroGen Pharma on 10 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and Spero Therapeutics' top-line revenue, earnings per share and valuation.

Aravive has higher earnings, but lower revenue than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and Spero Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 57.6% of Spero Therapeutics shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 17.4% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and Spero Therapeutics, as reported by MarketBeat.com.

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. Spero Therapeutics has a consensus price target of $32.75, suggesting a potential upside of 156.86%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than Spero Therapeutics.

Summary

Aravive beats Spero Therapeutics on 9 of the 13 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and VistaGen Therapeutics' top-line revenue, earnings per share and valuation.

Aravive has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and VistaGen Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 3.1% of VistaGen Therapeutics shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 13.7% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and VistaGen Therapeutics, as reported by MarketBeat.com.

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. VistaGen Therapeutics has a consensus price target of $5.6667, suggesting a potential upside of 116.28%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than VistaGen Therapeutics.

Summary

Aravive beats VistaGen Therapeutics on 9 of the 12 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and Foghorn Therapeutics' top-line revenue, earnings per share and valuation.

Foghorn Therapeutics has lower revenue, but higher earnings than Aravive.

Profitability

This table compares Aravive and Foghorn Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and Foghorn Therapeutics, as reported by MarketBeat.com.

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. Foghorn Therapeutics has a consensus price target of $24.6667, suggesting a potential upside of 142.07%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than Foghorn Therapeutics.

Summary

Aravive beats Foghorn Therapeutics on 5 of the 8 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Aravive and MEI Pharma's top-line revenue, earnings per share and valuation.

Aravive has higher earnings, but lower revenue than MEI Pharma. MEI Pharma is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aravive and MEI Pharma's net margins, return on equity and return on assets.

Insider & Institutional Ownership

40.5% of Aravive shares are owned by institutional investors. Comparatively, 67.6% of MEI Pharma shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 4.4% of MEI Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Aravive has a beta of 3.2, indicating that its stock price is 220% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Aravive and MEI Pharma, as reported by MarketBeat.com.

Aravive currently has a consensus price target of $25.20, suggesting a potential upside of 420.66%. MEI Pharma has a consensus price target of $10.60, suggesting a potential upside of 219.28%. Given Aravive's higher possible upside, research analysts plainly believe Aravive is more favorable than MEI Pharma.